PRODUCT OVERVIEW & COMPOSITION
Brand / Manufacturer: Bioniche Pharma
Active Ingredient: Drostanolone Enanthate (250 mg per ml)
Pharmacological Class: Synthetic Anabolic-Androgenic Steroid (Dihydrotestosterone / DHT derivative)
Bioniche Pharma Drostanolone Enanthate 250 mg is a long-acting injectable anabolic agent belonging to the dihydrotestosterone (DHT) family. Formulated with an enanthate ester to ensure sustained release, Bioniche Pharma Drostanolone Enanthate is highly valued for its potent intrinsic androgenic activity and natural anti-aromatase properties, making it an effective compound for promoting lean, defined tissue without estrogenic fluid retention.
CLINICAL PHARMACOLOGY & MECHANISM OF ACTION
Bioniche Pharma Drostanolone Enanthate binds selectively to cellular androgen receptors, significantly enhancing nitrogen retention and intracellular protein synthesis. Exogenous androgen administration via Bioniche Pharma Drostanolone Enanthate suppresses pituitary gonadotropin function, inhibiting endogenous luteinizing hormone (LH) and follicle-stimulating hormone (FSH) through negative feedback loops. Structurally, Bioniche Pharma Drostanolone Enanthate functions as a potent estrogen antagonist and does not aromatize into estrogen, effectively preventing estrogen-dependent side effects such as water retention, gynecomastia, and secondary hypertension.
INDICATIONS & CLINICAL USE
- Rapid restoration of skeletal muscle tissue atrophied during recovery from severe physical trauma or injury using Bioniche Pharma formulations.
- Therapeutic management to offset muscle catabolism and cachexia in chronic wasting syndromes under Bioniche Pharma treatment protocols.
- Adjunctive treatment for specific non-responsive anemias failing primary therapeutic agents with Bioniche Pharma anabolic support.
- Palliative estrogen-antagonistic therapy in select hormone-dependent advanced breast carcinoma cases under Bioniche Pharma medical oversight.
CONTRAINDICATIONS
- Contraindicated in women, children, and elderly individuals. Strictly prohibited during pregnancy or planned pregnancy due to severe fetal masculinization risks.
- Male patients with confirmed or suspected carcinoma of the prostate, testes, or breast.
- Patients with active renal failure, nephrosis, or the nephrotic phase of nephritis.
- Patients diagnosed with hypercalcemia, severe hepatic impairment, or existing cardiovascular conditions including hypertension, previous stroke, or heart disease.
- Patients with known hypersensitivity to Bioniche Pharma Drostanolone Enanthate, carrier oils, or excipients in Bioniche Pharma formulations.
PRECAUTIONS & PATIENT MONITORING
- Hepatic Surveillance: Elevated liver transaminases (AST, ALT, AP) and serum bilirubin may occur; periodic hepatic function testing is required during Bioniche Pharma therapy.
- Lipid & Cardiovascular Impact: Anabolic steroids increase LDL cholesterol and decrease HDL cholesterol. Baseline and periodic monitoring of serum lipid profiles (Cholesterol, HDL, LDL, Triglycerides) is recommended during Bioniche Pharma treatment.
- Coagulation Parameters: Bioniche Pharma Drostanolone Enanthate may reduce clotting factors II, V, VII, and X, prolonging prothrombin time (PT/INR). Patients taking oral anticoagulants (e.g., warfarin) require close oversight and dose adjustments.
- Prostatic Examinations: Male patients over 40 years should undergo digital rectal examinations and serum Prostate Specific Antigen (PSA) testing prior to and during Bioniche Pharma therapy.
- Comprehensive Lab Monitoring: Regular monitoring during Bioniche Pharma administration should include Hemoglobin/Hematocrit, total/free/bioavailable Testosterone, Dihydrotestosterone, and Estradiol levels.
ADVERSE REACTIONS
- Male & Endocrine: Excessive penile erections, priapism, oligospermia, suppression of gonadotropins, and changes in libido associated with Bioniche Pharma therapy.
- Dermatological: Acne vulgaris, oily skin, hirsutism, and accelerated male-pattern baldness (androgenetic alopecia) induced by Bioniche Pharma anabolic agents.
- Gastrointestinal & Hepatic: Nausea, cholestatic jaundice, altered liver function tests, and rarely, peliosis hepatis or hepatocellular neoplasms during Bioniche Pharma treatment.
- Fluid & Electrolyte: Retention of sodium, chloride, water, potassium, calcium, and inorganic phosphates, leading to potential edema and hypertension.
- Central Nervous System & Metabolic: Aggression, anxiety, mood changes, headaches, depression, reduced glucose tolerance, and potential exacerbation of sleep apnea under Bioniche Pharma administration.
DOSAGE & PRESENTATION
Presentation: Bioniche Pharma Drostanolone Enanthate 250 mg/ml (10 ml multi-dose vial).
Dosing protocols for Bioniche Pharma Drostanolone Enanthate must be individualized and strictly administered under direct medical supervision based on clinical objectives, laboratory findings, and overall patient response.
STORAGE & HANDLING
Store Bioniche Pharma products in a cool, dry place between 15°C and 25°C. Protect from direct exposure to light. Do not refrigerate or freeze Bioniche Pharma products. Keep strictly out of reach and sight of children.